Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should ximelagatran replace warfarin for stroke prevention in patients with atrial fibrillation?

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 278–279 (2005)Cite this article

boxed-textSPORTIF Executive Steering Committee for the SPORTIF V Investigators (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293: 690–698

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wolf PA et al. (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22: 983–988

    Article  CAS  Google Scholar 

  2. Hart RG et al. (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131: 492–501

    Article  CAS  Google Scholar 

  3. Eriksson BI et al. (2002) Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 360: 1441–1447

    Article  CAS  Google Scholar 

  4. Wallentin L et al. (2003) Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362: 789–797

    Article  CAS  Google Scholar 

  5. Olsson SB (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362: 1691–1698

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor and the Director of the National Stroke Research Institute at the University of Melbourne, Victoria, Australia

    Geoffrey A Donnan

  2. Research Fellow at the Austin Hospital and the National Stroke Research Institute, Victoria, Australia

    John V Ly

Authors
  1. Geoffrey A Donnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John V Ly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geoffrey A Donnan.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Donnan, G., Ly, J. Should ximelagatran replace warfarin for stroke prevention in patients with atrial fibrillation?. Nat Rev Cardiol 2, 278–279 (2005). https://doi.org/10.1038/ncpcardio0216

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0216

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing